Center for Organogenesis bridges scientific and clinical work on organ-specific diseases
The issue
Gary D. Hammer, M.D., Ph.D., understands the challenges of linking scientific research, or “bench work,” to a patient’s bedside. He leads the Multidisciplinary Endocrine Oncology Destination Program in the Comprehensive Cancer Center. It includes the Adrenal Cancer Program, one of only a few programs in the United States recognized as an international center of excellence for the treatment of adrenal cancer.
After many years of research and much collaboration, the adrenal team is beginning to identify a variety of genetic alterations that they hope will serve as targets for potential therapies. Indeed the program now coordinates most of the national and international clinical trials for adrenal cancer.
“Translational science is an interactive process of discovery,” Hammer says. “This requires a team approach. Since many faculty walk strictly along clinical or scientific lines, you need groups of scientists and clinicians who together can inform the bedside about the bench and vice versa.”
So, in a world where translational science has become a priority, how can we truly transform the University of Michigan into a translational campus? Hammer believes that scientists and clinicians who study the development of organs will play an essential role. And that’s where the U-M Center for Organogenesis comes in. Read the rest of this entry »











